Pfizer Inc

Pfizer managed to surpass the revenue and earnings expectations of analysts. Operationally, non-COVID-19 revenue increased, but total revenue decreased in the quarter. The projected revenue declines in both PAXLOVID and COMIRNATY principally brought on this loss. Besides that, the acquisitions of Biohaven and Global Blood Therapeutics contributed to Pfizer’s operational growth, while the Arena acquisition is projected to generate revenue by the end of this year. The management’s planned acquisition of Seagen, if authorized, is estimated to add more than $10 billion in sales by 2030. Furthermore, ELREXFIO is predicted to serve as the cornerstone of a multibillion-dollar franchise. This year, the FDA is anticipated to decide the potential first indication for the triple-class population with relapsed or refractory multiple myeloma, and they are progressing the clinical programs for MagnetisMM to open up early lines of treatment. In addition, the development of the GBS vaccine candidate fits in well with the favorable outcome and anticipated impending regulatory decision for the ABRYSVO. They also remain optimistic about receiving Phase II results from danuglipron by the end of 2023, allowing them to conclude their Phase III strategy.